Palisade Bio Initiates Phase 3 Study

Completion of enrollment for Phase 3 study targeted within 18-24 months

In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of costly post-surgery hospital stays

Phase 3 study design utilizes same dosing protocol and same primary endpoint as positive Phase 2 study that demonstrated 1.1-day improvement in return of bowel function

https://finance.yahoo.com/news/palisade-bio-initiates-phase-3-123000294.html